Antisense oligonucleotide-based therapeutics for cancer.
about
Improved targeting of miRNA with antisense oligonucleotidesTranslation of stable hepadnaviral mRNA cleavage fragments induced by the action of phosphorothioate-modified antisense oligodeoxynucleotidesTargeted therapy against Bcl-2-related proteins in breast cancer cellsTargeting Cell Survival Proteins for Cancer Cell DeathNucleic acid-based approaches to STAT inhibitionActivity, stability, and structure of metagenome-derived LC11-RNase H1, a homolog ofSulfolobus tokodaiiRNase H1Structure and characterization of RNase H3 from Aquifex aeolicusFormation of Oligonucleotide Adducts in Pharmaceutical FormulationsSelection of optimal antisense accessible sites of survivin and its application in treatment of gastric cancer.Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective.Evaluation of ultra high-performance [corrected] liquid chromatography columns for the analysis of unmodified and antisense oligonucleotidesPrelamin A and lamin A appear to be dispensable in the nuclear lamina.Collateral Lethality: A new therapeutic strategy in oncologyThe Effects of Stationary Phases on Retention and Selectivity of Oligonucleotides in IP-RP-HPLCReversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides.Polycomb-mediated silencing in neuroendocrine prostate cancer.Stabilization and photochemical regulation of antisense agents through PEGylation.Nucleic Acid Bioconjugates in Cancer Detection and Therapy.Transcription yield of fully 2'-modified RNA can be increased by the addition of thermostabilizing mutations to T7 RNA polymerase mutants.Oligonucleotides and polyribonucleotides: a review of antiviral activity.Antisense therapy for cancer.Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease miceEpigenetic manipulation of gene expression: a toolkit for cell biologistsLack of toxicity of a STAT3 decoy oligonucleotide.Phosphorothioate oligonucleotide quantification by μ-liquid chromatography-mass spectrometry.Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospects.Antisense-based cancer therapeutics: are we there yet?STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice.Nanoplasmonic gene regulationAdvances in experimental and translational research in the treatment of hepatocellular carcinomaCD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia.Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides.Activating the synthesis of progerin, the mutant prelamin A in Hutchinson-Gilford progeria syndrome, with antisense oligonucleotides.Biological barriers to therapy with antisense and siRNA oligonucleotides.Aptamers as theranostic agents: modifications, serum stability and functionalisationTargeting miRNAs in osteoblast differentiation and bone formation.Integrin targeted delivery of gene therapeuticsMicroRNAs and their roles in osteoclast differentiation.Cap-dependent translation initiation factor eIF4E: an emerging anticancer drug target.
P2860
Q24547511-8C3D3DE6-662A-4A7E-952E-391E8BCEDCDFQ24793675-C7658A2D-14AF-4336-81DF-5D02A221B582Q25257509-474D5086-1146-4311-9569-F1B12BEB4113Q26765447-4A5518F7-1982-4677-B986-7B118989162CQ26822830-68B57AC2-93DD-4077-AA88-0DE3B0DD7A2AQ27677834-9E5C7369-C76E-42BF-808B-4E3611E6C1DBQ27681104-04546031-10A7-437F-8AB4-53239355F635Q29998947-9D02DE98-CD40-4B98-9D5F-8926B8D0DD6AQ31142003-72110C83-0C9B-48F1-A809-91D60EF767F0Q33418637-14AF0B76-2005-44F1-A1B2-ABEC7AABECF1Q34389999-E58FB711-DEEF-4854-91EC-DD8E067E6B6FQ34416396-C5B82C8D-08F7-4083-92EF-ADF1D04334BCQ34513800-AF0E2F6C-FF80-466B-A39F-B17D7C0710EBQ34573751-22AC5C92-4BE2-4FF3-876F-44041D960C85Q35122908-D8ECE0F7-7802-4C8B-ADE5-C3F9B1E1C644Q35336915-32301B8C-6E1C-4505-AF95-2B59C40E7AD6Q35514689-A0111706-C831-4EEE-A0AF-7FFFEEB08240Q35867875-17A2567C-B623-4CDD-BFC1-400E095CA980Q36002517-CEF9008A-58C3-48E4-A4BB-B52A9ECF0E29Q36124734-AC2D1DC2-68D1-4164-B78B-97FC3F4A6F8DQ36133133-01216A97-798D-4B85-9608-4DA64FF81903Q36143261-315CC98F-016C-4DB9-B557-CA09A9436897Q36169056-53D542F6-7833-4D01-BF66-CB48F1DA0DF8Q36175325-01FD5B9A-444B-4B6E-90F6-38D73E430EEAQ36331548-40765DAC-193A-41AD-8FF3-6122E4EFB334Q36334885-27EBF6B8-9A66-4A1B-B4C0-A89825DDD2B6Q36458427-E89642B7-CFDA-47DC-A8FB-9577CD231C32Q36570495-2585B2FD-30E8-4816-BB03-6F5D3349A65FQ36733287-955978DF-ABE6-4859-8A0B-2E50389AA074Q37122717-B8F00619-FF18-41CD-8DD3-F064EDDDE701Q37130525-B3D68BEA-5253-41CC-B7E7-AB7FFB3A1B4FQ37189998-009ADFC1-B13F-4089-A772-8DA5CD06DB90Q37193000-ACF38E9A-721E-4B12-A658-43310AD65E1BQ37223285-1C0BFE1D-7B76-451C-8766-E6F04DA7F4BAQ37378340-78732F0B-2D1A-4439-91AC-66EF15D1CD8DQ37383122-ABCC5771-3F98-4413-9C5F-FB0F87EA7882Q37778399-B6C4F457-24E1-4662-81DA-C71D8D4BB1E6Q37872613-9ECF2949-B2E4-4BB5-BF2A-E5401CE39F32Q37971335-9AC267AB-B26C-481E-87F5-20D5A32BA878Q38001940-60123E11-FB85-469E-AC59-87F207F46696
P2860
Antisense oligonucleotide-based therapeutics for cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Antisense oligonucleotide-based therapeutics for cancer.
@ast
Antisense oligonucleotide-based therapeutics for cancer.
@en
type
label
Antisense oligonucleotide-based therapeutics for cancer.
@ast
Antisense oligonucleotide-based therapeutics for cancer.
@en
prefLabel
Antisense oligonucleotide-based therapeutics for cancer.
@ast
Antisense oligonucleotide-based therapeutics for cancer.
@en
P356
P1433
P1476
Antisense oligonucleotide-based therapeutics for cancer.
@en
P2093
C Frank Bennett
Nicholas M Dean
P2888
P304
P356
10.1038/SJ.ONC.1207231
P407
P577
2003-12-01T00:00:00Z
P5875
P6179
1029364204